跳至主要内容
临床试验/NCT01592162
NCT01592162已完成4 期

Dose-effect of Propofol for Anesthetic Induction: Double-blind Comparison of Different Propofol Formulations Administered Alone or With Remifentanil

Hopital Foch2 个研究点 分布在 1 个国家目标入组 409 人开始时间: 2013年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Hopital Foch
入组人数
409
试验地点
2
主要终点
necessary dose of propofol to obtain the induction of anesthesia (defined by a bispectral index < 60 over 30 continuous seconds)

研究概览

简要总结

The objective of this study is to evaluate the influence of different propofol formulations (plain or with remifentanil) on anesthetic induction. Propofol plain or with remifentanil is administered using a closed-loop algorithm in order to reach a Bispectral Index target of 50.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients scheduled for an intravenous induction of anesthesia with propofol

排除标准

  • Age under 18
  • Pregnancy or breastfeeding
  • Allergy to propofol, soya or peanuts,
  • Allergy to remifentanil,
  • History of central neurological disorder or brain injury,
  • Patients receiving psychotropic drugs,
  • Patient with a pacemaker

研究组 & 干预措施

propofol 1% (Astra-Zeneca) - remi 0

Active Comparator

propofol 1% (Astra-Zeneca)plus remifentanil 0 ng/ml

干预措施: Propofol (Astra-Zeneca), NaCl 0.9% (Drug)

propofol 1% (Astra-Zeneca) - remi 2

Active Comparator

propofol 1% (Astra-Zeneca)plus remifentanil 2 ng/ml

干预措施: propofol 1% (Astra-Zeneca) and remifentanil (Drug)

propofol 1% (Astra-Zeneca) - remi 4

Active Comparator

propofol 1% (Astra-Zeneca)plus remifentanil 4 ng/ml

干预措施: propofol 1% (Astra-Zeneca) and remifentanil (Drug)

propofol 1% (Fresenius) - remi 0

Active Comparator

propofol 1% (Fresenius) plus remifentanil 0 ng/ml

干预措施: Propofol (Astra-Zeneca), NaCl 0.9% (Drug)

propofol 1% (Fresenius) - remi 2

Active Comparator

propofol 1% (Fresenius) plus remifentanil 2 ng/ml

干预措施: Propofol (Astra-Zeneca) and remifentanil (Drug)

propofol 1% (Fresenius) - remi 4

Active Comparator

propofol 1% (Fresenius) plus remifentanil 4 ng/ml

干预措施: Propofol (Astra-Zeneca) and remifentanil (Drug)

propofol 1% (B-Braun) - remi 0

Active Comparator

propofol 1% (B-Braun) plus remifentanil 0 ng/ml

干预措施: Propofol (B-Braun) and NaCl 0.9% (Drug)

propofol 1% (B-Braun) - remi 2

Active Comparator

propofol 1% (B-Braun) plus remifentanil 2 ng/ml

干预措施: Propofol (B-Braun) and remifentanil (Drug)

propofol 1% (B-Braun) - remi 4

Active Comparator

propofol 1% (B-Braun) plus remifentanil 4 ng/ml

干预措施: Propofol (B-Braun) and remifentanil (Drug)

结局指标

主要结局

necessary dose of propofol to obtain the induction of anesthesia (defined by a bispectral index < 60 over 30 continuous seconds)

时间窗: one hour after anesthesia

次要结局

  • pain at injection(one hour after anesthesia)
  • patient's satisfaction(one day after anesthesia)
  • calculated concentrations of propofol at the end of the anesthetic induction(one hour after anesthesia)
  • Disappearance of the eyelash reflex(One hour after anesthesia)
  • heart rate modifications induced by anesthetic induction(one hour after anesthesia)
  • arterial pressure modifications induced by anesthetic induction(one hour after anesthesia)

研究者

发起方
Hopital Foch
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验